De-identified Health Data Market Top Companies Study - Shaip, Komodo Health, Inc., Evidation Health, Inc., Medidata, Clarify Health Solutions.

InsightAce Analytic Pvt. Ltd. Announces the release of a market assessment report on the "De-identified Health Data Market"-, By Type Of Data (Clinical, Genomic, Others), By End-use (Pharmaceutical Companies, Biotechnology Firms, Others), By Application (Clinical Research and Trials, Public Health, Precision Medicine, Health Economics and Outcomes Research (HEOR), Population Health Management, Drug Discovery and Development, Healthcare Quality Improvement, Insurance Underwriting and Risk Assessment, Market Access and Commercial Strategy, Business Intelligence and Operational Efficiency, Telemedicine and Remote Monitoring, Patient Engagement and Support Programs, Others), and Global Forecasts, 2024-2031 And Segment Revenue and Forecast To 2031."

The De-identified Health Data Market is estimated to reach over USD 13.77 billion by 2031, exhibiting a CAGR of 8.5% during the forecast period.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2850

De-identified health data refers to health information from which all personally identifiable information (PII) has been removed, ensuring that the data cannot be traced back to a specific individual. This process allows the data to be used for various research purposes without compromising patient confidentiality. It often involves replacing specific values with more general categories or removing identifying details altogether, enabling safe analysis and sharing of health data while maintaining privacy protections. De-identification is particularly important for government agencies, businesses, and other organizations that aim to make data available to external parties. It provides a significant benefit to AI-driven health research by limiting risks to patient privacy, while also maximizing the utility of health datasets by reducing the administrative burdens typically associated with conducting research.

The integration of genomics and clinical data is fundamental to precision medicine, enabling tailored treatments for individual patients based on their genetic makeup and medical history. De-identified genomics data allows researchers to study large populations and identify patterns in how specific genes influence diseases and treatment outcomes. When combined with clinical data, it becomes possible to create highly personalized therapeutic approaches without compromising patient privacy. Pharmaceutical companies and biotech firms increasingly rely on de-identified genomics and clinical data for drug discovery and development. By analyzing genetic variations alongside clinical outcomes, researchers can identify potential drug targets, optimize efficacy, and minimize adverse effects. The use of de-identified data ensures compliance with privacy regulations while allowing access to the vast datasets required for such breakthroughs. Both genomics and clinical data are essential for large-scale research, such as cohort studies and genome-wide association studies (GWAS), which require extensive datasets to identify correlations between genetic variations and health outcomes. De-identified data enables the secure sharing of this information across research institutions and companies, accelerating discovery and innovation.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

List of Prominent Players in the De-identified Health Data Market:
• IQVIA
• Oracle
• Merative
• Optum, Inc.
• ICON plc
• Veradigm LLC
• IBM
• Flatiron Health
• Premier, Inc.
• Shaip
• Komodo Health, Inc.
• Evidation Health, Inc.
• Medidata
• Clarify Health Solutions
• Satori Cyber Ltd.
• Kitware
• BioData Consortium
• Akrivia Health
• iMerit

Market Dynamics:
Drivers:
Innovations in de-identification techniques, including more sophisticated algorithms and automated tools, have made it easier for organizations to anonymize data effectively. These advances improve the balance between privacy protection and data utility, driving greater adoption of de-identification practices. Public health initiatives and pandemic response efforts, such as those seen during COVID-19, have increased the demand for de-identified health data. This data allows researchers and policymakers to track disease spread, evaluate healthcare interventions, and develop preventive measures on a large scale. The widespread use of EHRs has resulted in the collection of massive amounts of health data. Organizations are leveraging de-identified health data from EHR systems for research, clinical trials, and public health initiatives without compromising patient privacy.

Challenges:
De-identified health data is frequently sourced from a range of sources, including wearable technology, insurance claims, genetics, and clinical records. A major challenge can be integrating this data into a coherent, useable structure without jeopardizing patient privacy.

Regional Trends:
North America holds the largest share of the de-identified health data market, primarily due to the widespread adoption of electronic health records (EHRs) and advanced healthcare infrastructure. The U.S., in particular, is at the forefront due to its robust pharmaceutical and biotechnology sectors and leadership in AI-driven healthcare solutions. The Health Insurance Portability and Accountability Act (HIPAA) provides clear guidelines for the de-identification of health data, making it easier for organizations to share data for research while maintaining compliance. However, Asia Pacific rapidly growing region due to Governments and healthcare institutions in Asia-Pacific are increasingly focusing on personalized medicine and genomics research, particularly in countries like China and Japan. De-identified genomic and clinical data are critical to advancing these fields.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2850

Recent Developments:
• In Jun 2020, BARDA and Evidation Health to declare a collaboration with San Mateo, California-based Evidation Health to track medical personnel and emergency personnel by using patient-generated, de-identified health data from current wearables as an early warning system to spot COVID-19 signs in their early stages.
• In Sept 2019, Geisinger and IBM, revealed that they had collaborated to develop a novel prediction model that uses data gathered from the electronic health record of the integrated health system to assist clinicians in identifying patients at risk for sepsis.

Segmentation of De-identified Health Data Market
Global De-identified Health Data Market- By End Use
• Pharmaceutical Companies
• Biotechnology Firms
• Medical Device Manufacturers
• Healthcare Providers
• Insurance Companies/ Healthcare Payers
• Research Institutions
• Government Agencies
• Others
Global De-identified Health Data Market - By Application
• Clinical Research and Trials
• Public Health
• Precision Medicine
• Health Economics and Outcomes Research (HEOR)
• Population Health Management
• Drug Discovery and Development
• Healthcare Quality Improvement
• Insurance Underwriting and Risk Assessment
• Market Access and Commercial Strategy
• Business Intelligence and Operational Efficiency
• Telemedicine and Remote Monitoring
• Patient Engagement and Support Programs
• Others
Global De-identified Health Data Market - Type of Data
• Clinical Data
• Genomic Data
• Patient Demographics
• Prescription Data
• Claims Data
• Behavioral Data
• Wearable and Sensor Data
• Survey and Patient-Reported Data
• Imaging Data
• Laboratory Data
• Hospital and Provider Data
• Social Determinants of Health (SDoH) Data
• Pharmacogenomic Data
• Biometric Data
• Operational and Financial Data
• Epidemiological Data
• Healthcare Utilization Data
• Others
Global De-identified Health Data Market - By Region
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• Southeast Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of the Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2850

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.